Drug Delivery Nanoparticles Formulation Companies Market Position Advancements

Latest Updates of Companies in the Drug Delivery Nanoparticles Formulation Market

Recent Developments in the Drug Delivery Nanoparticles Formulation Market

• In October 2025, Gelteq Limited, a clinical and science-based organization specialising in gel-based oral delivery solutions, announced it had started a preclinical animal trial evaluating its proprietary formulation technology for oily and poorly soluble medicines.
• In January 2025, Evonik is partnering with ST Pharm, an organization that manufactures active ingredients for gene therapy, to increase its RNA and nucleic acid therapeutic services. Through the partnership, Evonik offers customized nucleic acids from ST Pharm alongside its portfolio of lipid and lipid nanoparticle (LNP) drug product development solutions.

Supply Chain Analysis

R&D:

• Research and development (R&D) in drug delivery nanoparticle formulation includes pre-formulation and design, formulation synthesis approaches, physicochemical characterization, stability assessment, in vitro performance evaluation, and scaling and regulatory processes.
• Key Players: Well Shield & Crystalplex

Manufacturing Processes:

• Manufacturing processes for drug delivery nanoparticles involve two main approaches: bottom-up, such as assembling molecules, and top-down, such as reducing bulk size.
• Key Players: DIANT Pharma and TRANSFERRA Nanosciences Inc.

Patient Services:

• Patient services in the drug delivery nanoparticles formulation include enhancing therapeutic effectiveness, safety, and compliance via targeted delivery, controlled release, and enhanced bioavailability.
• Key Players:Bristol-Myers Squibb and Ipsen & Insmed

Market Growth

The global drug delivery nanoparticles formulation market size was estimated at USD 92.6 billion in 2025 and is predicted to increase from USD 105.38 billion in 2026 to approximately USD 337.31 billion by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.